Human Metapneumovirus (HMPV): Symptoms, Diagnosis, and Treatment

---

Human Metapneumovirus (HMPV) is a respiratory virus that causes acute infections, especially in young children, the elderly, and those with weakened immune systems. A member of the Pneumoviridae family and closely related to respiratory syncytial virus (RSV), HMPV was first identified in 2001 in the Netherlands during research into unknown respiratory illnesses.

Symptoms can range from mild cold-like signs (cough, fever, nasal congestion) to severe lower respiratory issues like bronchiolitis or pneumonia, particularly in vulnerable individuals. The virus spreads through respiratory droplets, direct contact with infected secretions, or contaminated surfaces. HMPV is seasonal, peaking in late winter and spring in many regions. It is a common cause of respiratory disease worldwide, with nearly all children exposed by age five, according to seroprevalence studies.

Diagnosis requires molecular tests, such as RT-PCR, since symptoms alone are similar to those of other respiratory viruses. There is no specific antiviral treatment, so care focuses on hydration, fever management, and respiratory support in severe cases. Preventive measures include good hand hygiene, avoiding close contact with sick individuals, and cleaning surfaces. While no vaccine is available, research is underway due to the virus’s significant health impact.

Virology and Pathogenesis

HMPV is a single-stranded, negative-sense RNA virus, belonging to the family Pneumoviridae, closely related to the avian metapneumovirus. It shares many characteristics with respiratory syncytial virus (RSV), another common respiratory pathogen, but its genetic makeup and clinical presentation are distinct. HMPV has two main genetic lineages, A and B, each further divided into subgroups (A1, A2, B1, B2), which circulate variably from year to year.

The virus spreads primarily through respiratory droplets from coughing or sneezing, direct contact with infected secretions, or contact with contaminated surfaces. The incubation period lasts 3 to 6 days, and symptoms begin to manifest shortly thereafter.

Clinical Presentation

The clinical spectrum of HMPV infection ranges from mild upper respiratory symptoms, akin to a common cold, to severe lower respiratory tract infections like bronchiolitis and pneumonia. Typical symptoms include cough, fever, nasal congestion, and shortness of breath. In more severe cases, particularly among infants, older adults, or those with weakened immune systems, HMPV can lead to significant respiratory distress, requiring hospitalization.

Most individuals experience their first HMPV infection in early childhood, with reinfections being common throughout life due to only partial immunity following initial infection. This pattern mirrors that of other common respiratory viruses where reinfection can occur but often leads to milder symptoms in subsequent episodes.

Epidemiology

HMPV infections are seasonal, predominantly appearing in late winter and spring, though they can occur year-round. The virus has a global distribution, with serologic evidence suggesting that virtually all children have been exposed by age five. Studies indicate that HMPV contributes to 5-12% of respiratory illnesses in young children and can be as prevalent as RSV in some settings.

Diagnosis and Treatment

Diagnosis of HMPV can be challenging due to its similarity to other respiratory viruses. Molecular diagnostic techniques, like reverse transcriptase polymerase chain reaction (RT-PCR), are the most reliable for detection, especially since traditional viral cultures are slow and less sensitive. Testing is usually reserved for severe cases or outbreaks within healthcare settings.

Treatment for HMPV is primarily supportive, focusing on symptom relief; no specific antiviral therapy is currently available. This includes hydration, fever reduction, and, in more severe cases, oxygen therapy or mechanical ventilation. Preventive measures such as hand hygiene, avoiding close contact with sick individuals, and cleaning contaminated surfaces are crucial in controlling the spread.

Research and Vaccines

While no vaccines or specific treatments have been approved for HMPV, research is ongoing. Vaccine candidates have been tested in animal models, showing promise in inducing immune responses, but human clinical trials are yet to be conclusive. The challenges include the virus’ genetic variability and the need for vaccines to prevent primary and secondary infections.

Conclusion

Human metapneumovirus remains an under-recognized but significant cause of respiratory illness. Awareness and understanding of HMPV are crucial for managing outbreaks, especially in vulnerable populations such as children, the elderly, and those with compromised immunity.

Ongoing research into diagnostics, treatment strategies, and vaccine development continues to be vital in addressing the public health impact of this virus.

---

---

---

---

---

---

---